GlassScriptPhysician profile
Erin V Santa
NPI 1528329760
$3,457.08
in general payments reported to CMS, 2019-2025
28 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $213 · 2021: $400 · 2022: $465 · 2023: $955 · 2024: $839 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.77 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $798.65 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $564.40 | 2019-2024 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $233.06 | 2021-2024 | Olumiant, Taltz, Zepbound |
| Sun Pharmaceutical Industries INC. | $207.16 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $191.93 | 2021-2025 | |
| Allergan, INC. | $175.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $174.09 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $162.65 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $103.40 | 2023-2024 | Zoryve |
| Incyte Corporation | $100.58 | 2022-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $83.57 | 2019-2025 | Dupixent |
| Merz North America, INC. | $75.74 | 2019 | |
| Leo Pharma INC. | $70.56 | 2022-2023 | Adbry |
| Amgen INC. | $68.30 | 2023-2024 | Otezla |
| Prugen, INC. Pharmaceuticals | $58.30 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.78 | 2024 | |
| Dermira, INC. | $55.51 | 2019-2021 | |
| Ucb, INC. | $44.75 | 2021-2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $34.60 | 2024 | Ycanth |
| Sensus Healthcare, INC. | $33.38 | 2019 | |
| Galderma Laboratories, L.P. | $31.09 | 2020-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.19 | 2019-2021 | |
| Celgene Corporation | $22.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.76 | 2023 | Spevigo |
| Revance Therapeutics, INC. | $20.45 | 2025 | Daxxify |
| Dusa Pharmaceuticals, INC. | $16.23 | 2019 | |
| Dermavant Sciences, INC. | $14.72 | 2024 | Vtama |
| Organon LLC | $10.74 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Santa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.